KUL, P. Et Al. 2023. A Novel 6,8,9-Trisubstituted Purine Analogue Drives Breast Cancer Luminal A Subtype MCF-7 to Apoptosis and Senescence through Hsp70 Inhibition. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY , vol.23, no.5 , 585-598.

KUL, P., TUNÇBİLEK, M., ERGÜL, M., Tunoglu, E. N. Y., & Tutar, Y., (2023). A Novel 6,8,9-Trisubstituted Purine Analogue Drives Breast Cancer Luminal A Subtype MCF-7 to Apoptosis and Senescence through Hsp70 Inhibition. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY , vol.23, no.5, 585-598.

KUL, PINAR Et Al. "A Novel 6,8,9-Trisubstituted Purine Analogue Drives Breast Cancer Luminal A Subtype MCF-7 to Apoptosis and Senescence through Hsp70 Inhibition," ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY , vol.23, no.5, 585-598, 2023

KUL, PINAR Et Al. "A Novel 6,8,9-Trisubstituted Purine Analogue Drives Breast Cancer Luminal A Subtype MCF-7 to Apoptosis and Senescence through Hsp70 Inhibition." ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY , vol.23, no.5, pp.585-598, 2023

KUL, P. Et Al. (2023) . "A Novel 6,8,9-Trisubstituted Purine Analogue Drives Breast Cancer Luminal A Subtype MCF-7 to Apoptosis and Senescence through Hsp70 Inhibition." ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY , vol.23, no.5, pp.585-598.

@article{article, author={PINAR KUL Et Al. }, title={A Novel 6,8,9-Trisubstituted Purine Analogue Drives Breast Cancer Luminal A Subtype MCF-7 to Apoptosis and Senescence through Hsp70 Inhibition}, journal={ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY}, year=2023, pages={585-598} }